Therapeutic resistance and metastatic progression are responsible for the majority of cancer
mortalities. In particular, the development of resistance is a significant barrier to the efficacy …

Chemoresistance is one of the major challenges for the breast cancer treatment. Owing to its
heterogeneous nature, the chemoresistance mechanisms of breast cancer are complicated …

Aldehyde dehydrogenase (ALDH) is a superfamily of enzymes that detoxify a variety of
endogenous and exogenous aldehydes and are required for the biosynthesis of retinoic …

The human genome contains 19 putatively functional aldehyde dehydrogenase (ALDH)
genes, which encode enzymes critical for detoxification of endogenous and exogenous …

Breast cancer is a multifactorial disease and driven by aberrant regulation of cell signaling
pathways due to the acquisition of genetic and epigenetic changes. An array of growth …

Chemoresistant metastatic relapse of minimal residual disease plays a significant role for
poor prognosis of cancer. Growing evidence supports a critical role of cancer stem cell …

Triple negative breast cancers (TNBCs) are defined by the lack of estrogen receptor (ER),
progesterone receptor (PR), and human epidermal growth factor receptor 2 expression, and …

Female breast cancer is the world's most prevalent cancer in 2020. Chemotherapy still
remains a backbone in breast cancer therapy and is crucial in advanced and metastatic …

Simple Summary Cancer is one of the hardest pathologies to fight, being one of the main
causes of death worldwide despite the constant development of novel therapeutic strategies …

Aldehyde dehydrogenases (ALDHs) belong to a superfamily of enzymes that play a key role
in the metabolism of aldehydes of both endogenous and exogenous derivation. The human …